TABLE 5.
Antimicrobial resistance and serogroups between iNTS and non-iNTS infections in 2012 and 2019.
| iNTS |
non-iNTS |
|||||
| 2012 | 2019 | P value | 2012 | 2109 | P value | |
| Antimicrobial resistance | ||||||
| Ampicillin | 42.1% | 27.8% | 0.282 | 49.7% | 41.2% | 0.020 |
| Ceftriaxone | 10.5% | 5.6% | 0.602 | 3.8% | 15.1% | <0.001 |
| Ertapenem | 0% | 2.8% | 1.000 | 0% | 0.5% | 0.502 |
| Imipenem | 0% | 2.8% | 1.000 | 0% | 1.0% | 0.128 |
| Ciprofloxacin | 5.3% | 30.6% | 0.041 | 1.7% | 28.5% | <0.001 |
| TMP-SMX | 15.8% | 20.6% | 1.000 | 27.9% | 30.2% | 0.518 |
| Chloramphenicol | 21.2% | 60% | 0.126 | 21.8% | 30.9% | 0.005 |
| Flomoxef | 5.3% | 40% | 0.099 | 3.2% | 5.5% | 0.125 |
| MDR | 10.5% | 13.9% | 1.000 | 12.2% | 31.4% | <0.001 |
| Serogroups | ||||||
| B | 15.8% | 22.2% | 0.730 | 27.6% | 23.1% | 0.159 |
| C1 | 15.8% | 2.8% | 0.114 | 4.7% | 7% | 0.170 |
| C2 | 5.3% | 16.7% | 0.401 | 12.8% | 12.6% | 0.926 |
| D | 52.6% | 41.7% | 0.437 | 42.2% | 42.7% | 0.891 |
| E | 10.5% | 13.9% | 1.000 | 11% | 13.1% | 0.401 |
iNTS, invasive non-typhoidal Salmonella; MDR, multi-drug resistance, resistant to ≥3 drug classes; TMP-SMX, trimethoprim-sulfamethoxazole.